-
1 Comment
Jinhe Biotechnology CO., LTD is currently in a long term uptrend where the price is trading 9.0% above its 200 day moving average.
From a valuation standpoint, the stock is 78.2% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 2.1.
Jinhe Biotechnology CO., LTD's total revenue rose by 13.8% to $608M since the same quarter in the previous year.
Its net income has dropped by 63.1% to $15M since the same quarter in the previous year.
Finally, its free cash flow grew by 1203.4% to $23M since the same quarter in the previous year.
Based on the above factors, Jinhe Biotechnology CO., LTD gets an overall score of 4/5.
| Sector | Healthcare |
|---|---|
| Industry | Drug Manufacturers - Specialty & Generic |
| ISIN | CNE100001HK7 |
| Exchange | SHE |
| CurrencyCode | CNY |
| Beta | 0.51 |
|---|---|
| Market Cap | 5B |
| PE Ratio | 38.31 |
| Target Price | None |
| Dividend Yield | 1.6% |
Jinhe Biotechnology CO., LTD. produces and sells veterinary medicines in China and internationally. It offers chlortetracycline premixes; veterinary drug and powder series; disinfectants; and sprinklers. It also engages in the production and sales of feed and raw materials. The company was founded in 1990 and is headquartered in Hohhot, China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 002688.SHE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2026
